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Open access under CC BYVitamin B2 (riboﬂavin) is an essential dietary compound used for the enzymatic biosynthesis of FMN and
FAD. The human genome contains 90 genes encoding for ﬂavin-dependent proteins, six for riboﬂavin
uptake and transformation into the active coenzymes FMN and FAD as well as two for the reduction to
the dihydroﬂavin form. Flavoproteins utilize either FMN (16%) or FAD (84%) while ﬁve human ﬂavoen-
zymes have a requirement for both FMN and FAD. The majority of ﬂavin-dependent enzymes catalyze
oxidation–reduction processes in primary metabolic pathways such as the citric acid cycle, b-oxidation
and degradation of amino acids. Ten ﬂavoproteins occur as isozymes and assume special functions in
the human organism. Two thirds of ﬂavin-dependent proteins are associated with disorders caused by
allelic variants affecting protein function. Flavin-dependent proteins also play an important role in the
biosynthesis of other essential cofactors and hormones such as coenzyme A, coenzyme Q, heme, pyri-
doxal 50-phosphate, steroids and thyroxine. Moreover, they are important for the regulation of folate
metabolites by using tetrahydrofolate as cosubstrate in choline degradation, reduction of N-5.10-meth-
ylenetetrahydrofolate to N-5-methyltetrahydrofolate and maintenance of the catalytically competent
form of methionine synthase. These ﬂavoenzymes are discussed in detail to highlight their role in health
and disease.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Vitamin B2 (or riboﬂavin) is an essential dietary requirement for
humans (Homo sapiens sapiens) because the biosynthesis of this
compound is absent. The daily requirement for vitamin B2 was
estimated to be 1.1 mg and 1.3 mg for adult females and males,
respectively, but may vary depending on metabolic challenges
and the efﬁciency of riboﬂavin uptake. Dietary riboﬂavin is taken
up in the human gastrointestinal tract by poorly characterizedof Technology, Institute of
ax: +43 316 873 6952.
cheroux).
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-NC-ND license.transporters (Table 1, entry #74). Vitamin B2 is not used in any hu-
man enzyme per se but is chemically modiﬁed to the ﬂavin mono-
nucleotide (FMN)1 and ﬂavin adenine dinucleotide form by
riboﬂavin kinase (EC 2.7.1.26) and FAD synthetase (EC 2.7.7.2),
respectively. FMN and FAD as well as excess riboﬂavin are excreted
in the urine. Chastain and McCormick have also detected trace
amounts of 7-hydroxy- and 8-hydroxy-ﬂavins in human urine which
are generated through as yet unknown catabolic reactions [1]. In
addition, they have also found 8-sulfonyl-ﬂavin which is supposedly
released from enzymes bearing a covalent thioester linkage, e.g.
monoamine oxidase A and B (MAOA and MAOB, Table 1).
FMN and FAD possess a tricyclic heteroaromatic isoalloxazine
ring that can reversibly accept and donate one or two electrons.
Thus the majority of the enzymes utilizing FMN or FAD catalyze
reduction–oxidation (‘‘redox’’) reactions in metabolic transforma-
tions. In fact, the majority of human ﬂavoenzymes belongs to the
oxidoreductases with only two example each for a transferase
and lyase, respectively (Table 1, entries #65–68). Flavoenzymes
may either use FMN or FAD as cofactor and most are speciﬁc for
one or the other. In the case of human ﬂavoproteins only twelve
use FMN and 64 FAD as cofactor amounting to ca. 16% and 84%
of the ﬂavoenzymes, respectively (note that ﬁve enzymes utilize
both FMN and FAD). In a global analysis of FMN and FAD usage
in ﬂavoproteins it was noted that 25% of ﬂavoenzymes utilize
FMN [2], hence the human ﬂavoproteome has a clear bias towards
FAD-dependent enzymes.
Table 1
Human ﬂavoproteins.
No. E.C. Enzyme Cofactor Structure clan (family)* Gene symbol Gene location
1 1.1.1.28 D-lactate dehydrogenase FAD FAD_PCMH (FAD_binding_4) LDHD 16q23.1
2 1.1.1.204 Xanthine dehydrogenase FAD FAD_PCMH (FAD_binding_5) XDH 2p23.1
3 1.1.3.15 (S)-2-hydroxy-acid oxidase FMN TIM_barrel (FMN_dh) HAO1 20p12.3
HAO2 1p12
4 1.1.5.3 Glycerol 3-phosphate dehydrogenase FAD NADP_Rossmann (DAO) GPD2 2q24.1
5 1.1.99.1 Choline dehydrogenase FAD GMC_ oxred CHDH 3p21.1
6 1.1.99.2 L-2-Hydroxyglutarate dehydrogenase FAD ———————————————————————————————————— L2HGDH 14q21.3
7 1.1.99.- D-2-Hydroxyglutarate dehydrogenase FAD ———————————————————————————————————— D2HGDH 2q37.3
8 1.2.3.1 Aldehyde oxidase FAD ———————————————————————————————————— AOX1 2q33.1
9 1.3.1.2 Dihydropyrimidine dehydrogenase FMN TIM_barrel (DHO_dh) DPYD 1p21.3
FAD NADP_Rossmann (Pyr_redox_2)
10 1.3.1.72 3b-Hydroxysterol D24-reductase FAD ———————————————————————————————————— DHCR24 1p32.3
11 1.3.3.1 Dihydroorotate dehydrogenase FMN TIM_barrel (DHO_dh) DHODH 16q22.2
12 1.3.3.4 Protoporphyrinogen IX oxidase FAD NADP_Rossmann (Amino_oxidase) PPOX 1q23.3
13 1.3.3.6 Acyl-CoA oxidase FAD Acyl-CoA_dh ACOX1 17q25.1
(ACOX, acyl-CoA_dh_1) ACOX2 3p14.3
ACOX3 4p16.1
14 1.3.3.- Glutaryl-CoA oxidase FAD ———————————————————————————————————— C7orf10 7p14.1
15 1.3.5.1 Succinate dehydrogenase 8a-(N3-His)- NAPH_Rossmann (FAD_binding_2) SDHA 5p15.33
Flavoprotein subunit A -FAD (3q29)a
16 1.3.99.2 Short-chain- (butyryl-) acyl CoA dehydrogenase FAD Acyl-CoA_dh (Acyl_CoA_dh_1) ACADS 12q24.31
17 1.3.99.3 Medium-chain acyl-CoA dehydrogenase FAD Acyl-CoA_dh (Acyl_CoA_dh_1) ACADM 1p31.1
18 1.3.99.7 Glutaryl-CoA dehydrogenase FAD Acyl-CoA_dh (acyl-CoA_dh_1) GCDH 19p13.2
19 1.3.99.10 Isovaleryl-CoA dehydrogenase FAD Acyl-CoA_dh (acyl-CoA_dh_1) IVD 15q15.1
20 1.3.99.12 2-Methylbutyryl-CoA dehydrogenase FAD Acyl-CoA_dh (acyl-CoA_dh_1) ACADSB 10q26.13
21 1.3.99.13 Long-chain-acyl-CoA dehydrogenase FAD Acyl-CoA_dh (acyl-CoA_dh_1) ACADL 2q34
22 1.3.99.- Very long-chain acyl-CoA dh FAD Acyl-CoA_dh (acyl-CoA_dh_1) ACADVL 17p13.1
23 1.3.99.- Isobutyryl-CoA dehydrogenase FAD Acyl-CoA_dh (acyl-CoA_dh_1) ACAD8 11q25
24 1.3.99.- Long-chain-unsaturated-acyl-CoA dh (molecular chaperone of complex I) FAD Acyl-CoA_dh (acyl-CoA_dh_1) ACAD9 3q21.3
25 1.3.99.- Long- and branched-chain-acyl-CoA dh FAD Acyl-CoA_dh (acyl-CoA_dh_1) ACAD10 12q24.1
26 1.3.99.- C22-long-chain-acyl-CoA dehydrogenase FAD Acyl-CoA_dh (acyl-CoA_dh_1) ACAD11 3q22.1
27 1.4.3.1 D-aspartate oxidase FAD NADP_Rossmann (DAO) DDO 6q21
28 1.4.3.2 L-amino acid oxidase FAD NADP_Rossmann (Amino_oxidase) LAO 19q13.3-q13.4
29 1.4.3.3 D-amino acid oxidase FAD NADP_Rossmann (DAO) DAO 12q24.11
30 1.4.3.4 Monoamine oxidase 8a-(Cys)-FAD NADP_Rossmann (Amino_oxidase) MAOA Xp11.3
MAOB Xp11.3b
31 1.4.3.5 Pyridoxal 5’-phosphate oxidase FMN FMN-binding (Pyridox_oxidase) PNPO 17q21.32
Pyridoxine 5’-phosphate oxidase
32 1.4.3.- Catecholamine oxidase (renalase) FAD NADP_Rossmann (Amino_oxidase) RNLS 10q23.31
33 1.5.1.20 Methylenetetrahydrofolate reductase FAD FAD_oxidored (MTHFR) MTHFR 1p36.22
34 1.5.3.7 L-pipecolate oxidase 8a-(Cys)-FAD NADP_Rossmann (DAO) PIPOX 17q11.2
35 1.5.3.16 Spermine oxidase FAD NADP_Rossmann (Amino_oxidase) SMO 20p13
36 1.5.5.1 Electron-transferring ﬂavoprotein-ubiquinone oxidoreductase FAD 4Fe-4S (ETF_QO) ETFDH 4q32.1
37 —————— Electron transferring ﬂavoprotein FAD FAD_DHS (ETF_alpha) ETFA 15q24.2-q24.3
HUB (ETF) ETFB 19q13.41
38 1.5.99.1 Sarcosine dehydrogenase 8a-(N3-His)- NADP_Rossmann (DAO) SARDH 9q34.2
-FAD
39 1.5.99.2 Dimethylglycine dehydrogenase 8a-(N3-His) NADP_Rossmann (DAO) DMGDH 5q14.1
-FAD
40 1.5.99.- Lysine-speciﬁc histone demethylase FAD NADP_Rossmann KDM1A 1p36.12
41 1.5.99.8 Proline dehydrogenase FAD FAD_oxidored (Pro_dh) PRODH 22q11.21
(continued on next page)
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Table 1 (continued)
No. E.C. Enzyme Cofactor Structure clan (family)* Gene symbol Gene location
42 1.6.2.2 Cytochrome-b5 reductase FAD FAD_Lum_binding (FAD_binding_6) CYB5R3 22q13.2
43 1.6.2.4 NADPH-hemoprotein reductase FMN Flavoprotein (ﬂavodoxin_1) POR 7q11.23
(cytochrome P450 reductase) FAD FAD_Lum_binding (FAD_binding_1)
44 1.6.5.2 NAD(P)H dehydrogenase (quinone) FAD Flavoprotein (Flavodoxin_2) NQO1 16q22.1
45 1.6.5.3 NADH-ubiquinone oxidoreductase of complex I, subunit UQOR1 FMN complex1_51K NDUFV1 11q13.2
46 1.6.-.- NADPH-dep. diﬂavin oxidoreductase 1 FMN Flavoprotein (Flavodoxin_1) NDOR1 9q34.3
FAD FAD_Lum_binding (FAD_binding_1)
47 1.6.-.- tRNA dihydrouridine synthase FMN TIM_barrel (Dus) DUS2L 16q22.1
48 1.8.1.4 Dihydrolipoyl dehydrogenase FAD NADP_Rossmann (Pyr_redox_2) DLD 7q31.1
49 1.8.1.7 Glutathione-disulﬁde reductase FAD NADP_Rossmann (Pyr_redox_2) GSR 8p12
50 1.8.1.9 Thioredoxin-disulﬁde reductase FAD NADP_Rossmann (Pyr_redox_2) TXNR1 12q23.3
TXNR2 22q11.21
TXNR3 3q21.3
51 1.8.1.- ER ﬂavoprotein associated with degr. FAD ———————————————————————————————————— FOXRED2 22q12.3
52 1.8.3.2 Sulfhydryl oxidase FAD Erv1_Alr GFER 16p13.3
53 1.8.3.5 Prenylcysteine oxidase FAD ———————————————————————————————————— PCYOX1 2p13.3
54 1.10.99.2 Ribosyldihydronicotinamide FAD Flavoprotein (Flavodoxin_2) NQO2 6p25.2
dehydrogenase
55 1.14.13.8 Flavin-containing monooxygenases FAD ———————————————————————————————————— FMO1 1q24.3
FMO2 1q24.3
FMO3 1q24.3
FMO4 1q24.3
FMO5 1q21.1
56 1.14.13.9 Kynurenine 3-monooxygenase FAD ———————————————————————————————————— KMO 1q43
57 1.14.13.39 Nitric-oxide synthase FMN Flavoprotein (Flavodoxin_1) NOS1 12q24.22
FAD FAD_Lum_binding (FAD_binding_1) NOS2 17q11.2
NOS3 7q36.1
58 1.14.13.132 Squalene monooxygenase FAD ———————————————————————————————————— SQLE 8q24.13
59 1.14.99.- Monooxygenase in coenzyme Q biosyn. FAD? ———————————————————————————————————— COQ6 14q24.3
60 1.16.1.2 Ferrireductase (biliverdin IX beta red.) FMN? N-terminal domain (1-215) STEAP3 2q14.2
61 1.16.1.8 Methionine synthase reductase FMN Flavoprotein (Flavodoxin_1) MTRR 5p15.31
FAD FAD_Lum_binding (FAD_binding_1)
62 1.18.1.2 Ferredoxin-NADP+ reductase FAD FAD_Lum_binding (FAD_binding_6) FDXR 17q25.1
63 1.-.-.- NAD(P)H oxidase cytochrome b(558), beta subunit FAD ———————————————————————————————————— CYBB Xp11.4
64 1.-.-.- Thyroid oxidase / dual oxidase FAD ———————————————————————————————————— DUOX1 15q21.1
DUOX2 15q21.1
65 2.2.1.6 Acetolactate synthase-like protein FAD? ———————————————————————————————————— - 19p13.12
66 2.5.1.26 Alkyldihydroxyacetone phosphate synthase FAD FAD_PCMH (FAD_binding_4) AGPS 2q31.2
67 4.1.1.36 4’-Phosphopantothenoylcysteine decarboxylase FMN Flavoprotein PPCDC 15q24.2
68 4.1.99.3 Cryptochrome FAD FAD-binding of DNA-photolyase CRY1 12q23.3
(FAD_binding_7) CRY2 11p11.2
69 —————— Apoptosis inducing protein FAD NADP_Rossmann (Pyr_redox_2) AIFM1 Xq26.1
70 —————— Apoptosis inducing protein 6-OH-FAD NADP_Rossmann (Pyr_redox_2) AIFM2 10q22.1
71 —————— Iodotyrosine deiodinase FMN Nitroreductase IYD 6q25.1
72 —————— Axon guidance protein FAD NADP_Rossmann (FAD_binding_3) MICAL1 6q21
Interacting with CasL MICAL2 11p15.3
MICAL3 22q11.21
73 —————— FAD-dependent oxidoreductase (molecular chaperone of complex 1) FAD ———————————————————————————————————— FOXRED1 11q24.2
74 —————— Riboﬂavin transporter Riboﬂavinc ———————————————————————————————————— SLC52A1 17p13.2
SLC52A2 8q24.3
SLC52A3 20p13
75 1.5.1.30 Riboﬂavin / FMN reductase FMNc NADP_Rossmann (NmrA-like) BLVRB 19q13.2
76 2.7.1.26 Riboﬂavin kinase riboﬂavinc Flavokinase RFK 9q21.13
77 2.7.7.2 FAD-adenylyl transferase (synthetase) FMNc HUP (PAPS_reduct) FLAD1 1q21.3
Abbreviations used: biosyn., biosynthesis; dh, dehydrogenase; degr., degradation; dep., dependent; ER, endoplasmic reticulum; red., reductase.
* Pfam classiﬁcation given in plain text is for the structure of human proteins and those in italics for structures of homologs.
a Duplicated pseudogene.
b Opposite orientation on chromosome.
c Substrate of transporter, modifying enzyme or reductase (entries 74–77).
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Table 2
Disease-related human ﬂavoproteins.
No. E.C. Enzyme Disease Metabolic function Localisation OMIM
1 1.1.1.204 Xanthine dehydrogenase Xanthinuria type I Purine degr. Cytosol 607633
2 1.1.5.3 Glycerol 3-phosphate
dehydrogenase
Diabetis mellitus type II Electron transport mito. i.
membr.
138430
3 1.1.99.1 Choline dehydrogenase tooth agenesis, cleft lip
sperm motility
Choline degr. mito. i.
membr.
[78–
82]
4 1.1.99.2 L-2-Hydroxyglutarate
dehydrogenase
L-2-Hydroxyglutaric
aciduria
‘‘Metabolite repair’’ mito. membr. 609584
5 1.1.99.- D-2-Hydroxyglutarate
dehydrogenase
D-2-Hydroxyglutaric
aciduria
‘‘Metabolite repair’’ Mitochondria 605176
6 1.3.1.2 Dihydropyrimidine
dehydrogenase
Deﬁciency Pyrimidine catab. Cytosol 612779
7 1.3.1.72 3b-Hydroxysterol D24-
reductase
Desmosterolosis Sterol biosyn. ER membr. 606418
8 1.3.3.1 Dihydroorotate
dehydrogenase
Miller syn. Please specify the signiﬁcance of footnote ‘‘a’’ cited in the
Table 2, as a corresponding footnote text has not been
provided.
mito. i.
membr.
126064
9 1.3.3.4 Protoporphyrinogen IX
oxidase
Variegate porphyria Heme biosyn. Mito. i.
membr.
600923
10 1.3.3.6 Acyl-CoA oxidase Deﬁciency Lipid degr. Peroxisomes 609751
11 1.3.3.- Glutaryl-CoA oxidase Glutaric aciduria III Glutaryl degr. Peroxisomes 231690
12 1.3.5.1 Succinate dehydrogenase Complex II deﬁciency Citric acid cycle mito. i.
membr.
600857
Flavoprotein subunit A Leigh syn.
paraganglioma 5
13 1.3.99.2 Short-chain- (butyryl-) acyl
CoA dehydrogenase
Deﬁciency b-Oxidation mito. matrix 201470
14 1.3.99.3 Medium-chain acyl-CoA
dehydrogenase
Deﬁciency b-Oxidation mito. matrix 607008
15 1.3.99.7 Glutaryl-CoA dehydrogenase Glutaric acidemia Lysine degr. mito. matrix 608801
16 1.3.99.10 Isovaleryl-CoA
dehydrogenase
Isovaleric acidemia Leucine degr. mito. matrix 607036
17 1.3.99.12 2-Methylbutyryl-CoA
dehydrogenase
Deﬁciency Isoleucine degr. mito. matrix 600301
18 1.3.99.13 Long-chain-acyl-CoA
dehydrogenase
Deﬁciency b-Oxidation mito. matrix 609576
19 1.3.99.- Isobutyryl-CoA
dehydrogenase
Deﬁciency Valine degr. mito. matrix 611283
20 1.3.99.- Long-chain-unsaturated-acyl-
CoA dehydrogenase
Deﬁciency b-Oxidation mito. matrix 611126
21 1.3.99.- very long-chain acyl-CoA
dehydrogenase
Deﬁciency b-oxidation mito. matrix 201475
22 1.4.3.3 D-amino acid oxidase Schizophrenia?
amyotrophic lateral
sclerosis
Oxidation of D-serine Peroxisomes 124050
23 1.4.3.4 Monoamine oxidase Brunner syn. antisocial
behaviour autism
Oxidation of neuro-transmitter mito. o.
membr.
309850
24 1.4.3.5 Pyridoxal 5’-phosphate
oxidase
Encephalopathy Vitamin B6 metab. Cytosol 603287
Pyridoxine 5’-phosphate
oxidase
25 1.4.3.- Catecholamine oxidase
(renalase)
Hypertension? Oxidation Secreted
(Blood)
609360
26 1.5.1.20 Methylenetetrahydrofolate
reductase
Homocystinuria neural
tube defects
schizophrenia
Folate metab. Cytosol 607093
27 1.5.5.1 Electron-transferring
ﬂavoprotein-ubiquinone
oxidoreductase
Glutaric acidemia IIC Electron transport mito. i.
membr.
231675
28 —————— Electron transferring
ﬂavoprotein
Glutaric acidemia IIA Electron transport mito. matrix 608053
Glutaric acidemia IIB Electron transport 130410
29 1.5.99.1 Sarcosine dehydrogenase Sarcosinemia Choline degr. mito. matrix 604455
30 1.5.99.2 Dimethylglycine
dehydrogenase
DMGDH-deﬁciency Choline degr. mito. matrix 605850
31 1.5.99.8 Proline dehydrogenase Hyperprolinemia type I
schizophrenia
Amino acid metab. 606810
32 1.6.2.2 Cytochrome-b5 reductase Methemoglobinemia
type I and II
Heme metab. membr.
soluble
(erythro.)
613213
33 1.6.2.4 NADPH-hemoprotein
reductase
Antley-Bixler syn.
Disordered
steroidogenesis
Electron donor to P450 enzymes Microsomes
(ER)
124015
(cytochrome P450 reductase)
34 1.6.5.2 NAD(P)H dehydrogenase
(quinone)
Benzene toxicity breast
cancer
Quinone detox p53 degr. Cytosol 125860
(continued on next page)
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Table 2 (continued)
No. E.C. Enzyme Disease Metabolic function Localisation OMIM
35 1.6.5.3 NADH-ubiquinone
oxidoreductase
Complex I deﬁciency Electron transport mito. i.
membr.
161015
36 1.8.1.4 Dihydrolipoyl dehydrogenase Leigh syn. Maple syrup
urine dis., III
Energy metab. mito. matrix 238331
37 1.8.1.7 Glutathione-disulﬁde
reductase
Hemolytic anemia detox. Cytosol
(erythro.)
138300
38 1.8.3.2 Sulfhydryl oxidase Myopathy Disulﬁde redox balance mito. im.
space
600924
39 1.10.99.2 Ribosyldihydronicotinamide
dehydrogenase
Breast cancer
susceptibility
Quinone detox. Cytosol 160998
40 1.14.13.8 ﬂavin-containing
monooxygenases
trimethylaminuria detox. microsomes
(ER)
136132
41 1.14.13.39 Nitric-oxide synthase Hypertension Vasodilation Cytosol 163729
163730
42 1.14.99.- Monooxygenase in coenzyme
Q biosyn.
Deﬁciency/nephrotic
syn.
Coenzyme Q biosyn. Golgi/mito. 614647
43 1.16.1.8 Methionine synthase
reductase
Homocystinuria neural
tube defects
Methionine biosyn. Cytosol 602568
44 1.-.-.- NAD(P)H oxidase Chronic granulomatous
dis.
Generation of superoxide Phagocytes 300481
Cytochrome b(558), beta
subunit
Atypical
mycobacteriosis
(membr.)
45 1.-.-.- Thyroid oxidase/dual oxidase Thyroid
dishormonogenesis 6
Thyroid biosyn. membr. 606759
46 2.5.1.26 Alkyldihydroxyacetone
phosphate synthase
Rhizomelic chondrodys-
plasia punctata, type 3
Lipid biosyn. Peroxisomes 603051
47 —————— Apoptosis inducing protein Combinded oxidative
phosphorylation
deﬁciency
Redox control mito./
nucleus
300169
48 —————— Iodotyrosine deiodinase Thyroid
dyshormonogenesis
type 4
Iodide salvage Cytosol 612025
49 —————— FAD-dependent
oxidoreductase
complex I deﬁciency
Leigh syn.
Molecular chaperone mito. matrix 613622
50 —————— Riboﬂavin transporter
(member 3)
Brown-Vialetto-Van
Laere syn. Fazio-Londe
dis.
Riboﬂavin uptake membr. 613350
Abbreviations used: biosyn., biosynthesis; catab., catabolism; degr., degradation; detox., detoxiﬁcation; dim., diminished; dis., disease; metabol., metabolism; mito.,
mitochondrium; mito. i. membr., inner membrane of mitochondria; mito. o. membr., outer membrane of mitochondria; mito. im. space, mitochondrial intermembrane space;
ER, endoplasmic reticulum; membr., membrane; syn., syndrome; erythro., erythrocytes.
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six human ﬂavoenzymes the FAD cofactor is covalently linked via
the 8-a-methyl group to either the nitrogen (N-3) of a histidine
(succinate, sarcosine and dimethylglycine dehydrogenase) or the
sulfur of a cysteine residue (MAOA, MAOB and L-pipecolate oxi-
dase). Interestingly, monocovalent attachment to the 6-position
of the isoalloxazine ring system as well as bicovalent attachment
to the 8-a and 6-position observed in several bacterial, fungal
and plant ﬂavoenzymes are absent in human ﬂavoproteins. This
is also reﬂected by the scarcity of ﬂavoenzymes adopting a topol-
ogy similar to the p-cresolmethylhydroxylase (clan FAD_PCMH,
family FAD_binding_4) with D-lactate dehydrogenase (EC
1.1.1.28) and alkalidihydroxyacetone phosphate synthase (EC
2.5.1.26) as sole examples for this type of structure. Interestingly,
these two enzymes represent a subset of ﬂavoenzymes in this clan
that does not engage in covalent linkage of the FAD cofactor, which
in fact appears to be the rule rather than the exception in this
structure family [2]. Overall, it is encouraging that the structure
of more than half of the human ﬂavoproteins was solved by X-
ray crystallography (Table 1). In addition, in 23 cases the structure
of the human protein can be inferred from the known structure of a
homologous ﬂavoprotein. This leaves only ﬁfteen ﬂavoproteins
where currently no structural information is available (Table 1).
The prevalence of the Rossmann-fold in FAD-dependent ﬂavoen-
zymes previously noted [2] is also seen in the human FAD-depen-
dent proteins (see Fig. S1). In contrast to the global fold
distribution the structural clan Acyl-CoA_dh takes second placeand switches place with the clan FAD_PCMH. This is due to the rel-
atively large number of acyl-CoA dehydrogenases (eleven) and
acyl-CoA oxidases (three) compared to only three members in
the FAD_PCMH clan. Flavoenzymes in the latter clan appear to be
rare in mammals but are very prominent in metabolically active
and diverse organisms such as bacteria, fungi and plants [2]. The
most common structural clan found for human FMN-dependent
proteins is Flavoprotein and TIM_barrel (ﬁve and four members,
respectively, see Fig. S1) and reﬂects the general prevalence of
these two clans in FMN-dependent ﬂavoproteins [2].
The chromosomal location of the genes encoding ﬂavoproteins
is known for all ﬂavoproteins (Table 1 and Fig. S2). They are uni-
formly distributed over the chromosomes with only chromosome
13, 18, 21 and Y lacking genes encoding ﬂavoproteins (Table 1
and Fig. S2). Eleven ﬂavoenzymes occur as isozymes encoded by
multiple genes (2–5). In three cases (DUOX1–2, FMO1–5 and
MAOA + B) the genes are on the same chromosome (15, 1 and X,
respectively) whereas in all other cases (ACOX1–3, CRY1–2,
HAO1–2, MICAL1–3, NOS1–3 and SLC52A1–3) the genes are on dif-
ferent chromosomes (Fig. S2).Flavoenzymes in human diseases
A surprisingly large number of ﬂavoproteins (ca. 60%) is associ-
ated with human disorders caused by mutations in the pertinent
gene. Table 2 provides an overview of the 50 ﬂavoproteins along
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voproteins are localized in the mitochondria the diseases are con-
nected with deﬁciencies in mitochondrial processes. Other
compartments, most notably peroxisomes and the endoplasmic
reticulum, are also affected by some ﬂavoprotein deﬁciencies or
dysfunctions. In several cases ﬂavoprotein deﬁciencies occur in
connected metabolic pathways and therefore give rise to similar
clinical manifestations. For example, glutaric acidemia (OMIM
608801) can be caused by a deﬁciency of glutaryl-CoA dehydroge-
nase (type I), electron transferring ﬂavoprotein (type IIA and IIB) or
electron-transferring ﬂavoprotein-ubiquinone oxidoreductase
(type IIC). Similarly, Leigh syndrome (OMIM 256000) may arise
from a defect in any of the respiratory electron transfer complexes
in the inner mitochondrial membrane and thus deﬁciency of com-
plex I (containing the FMN-dependent NDUFV1) or complex II
(containing the FAD-dependent subunit A) as well as FOXRED1,
an FAD-containing molecular chaperone of complex I, may consti-
tute the molecular cause of the disease.
Since mutations are generally irreversible, adverse effects on
the biological function of an encoded protein are untreatable and
therapeutic interventions rely on protein substitution or, in the fu-
ture, gene therapy. For several ﬂavoproteins it was found that the
mutation led to an amino acid exchange affecting the binding afﬁn-
ity of the ﬂavin cofactor. In these cases it is conceivable that high-
dose riboﬂavin supplementation may increase the concentration of
ﬂavin cofactors and this in turn may increase the fraction of active
holo-enzyme. Ames and coworkers have compiled a list of ﬂavoen-
zymes with decreased cofactor afﬁnity where this strategy may be
exploited successfully [3]. Among the ﬂavoenzymes discussed are
N-5,10-methylenetetrahydrofolate reductase (EC 1.5.1.20, MTHFR),
NAD(P):quinone oxidoreductase (EC 1.6.5.2, NQO1), protoporphy-
rinogen IX oxidase (EC 1.3.3.4, PPOX), electron transferring ﬂavo-
protein (ETF), electron-transferring ﬂavoprotein ubiquinone
oxidoreductase (EC 1.5.5.1, ETFDH), glutaryl-CoA oxidase (EC
1.3.3.-, C7orf10), short-, medium-, long-chain acyl-CoA dehydro-
genases (EC 1.3.99.2, ACADS; EC 1.3.99.3, ACADM; EC 1.3.99.13,
ACADL) and complex I (EC 1.6.5.3, NDUFV1) [3]. More recently, it
was shown that the neurological disorders Brown–Vialetto–Van
Laere and Fazio-Londe syndrome were caused by mutations in
the gene encoding an intestinal riboﬂavin transporter [4,5]. Since
this transporter is largely unexplored, the effect of the mutation
on riboﬂavin transport efﬁciency is currently unknown. However,
it appears that at least in some patients riboﬂavin supplementation
ameliorates the symptoms and positively affects disease progres-
sion [4,6,7]. Apart from a few ﬂavoproteins with decreased afﬁnity
for cofactor mentioned by Ames and coworkers [3] it is largely un-
known how mutations in genes encoding ﬂavoproteins impact
cofactor binding. In view of the large number of ﬂavoproteins in-
volved in human diseases it is worthwhile investigating the muta-
tional effects on cofactor binding to thoroughly evaluate the
beneﬁts of high-dose riboﬂavin supplementation therapy (see also
discussion below).Flavoenzymes in cofactor biogenesis and metabolism
FMN and FAD are synthesized in the human organism from
riboﬂavin (vitamin B2) by riboﬂavin kinase (EC 2.7.1.26) and
FAD-adenylyl transferase (EC 2.7.7.2). Riboﬂavin is absorbed from
nutrients as is the case for many other vitamins required to supply
vitamin-derived coenzymes to the apo-forms of hundreds of en-
zymes in the human body. In this context, we were intrigued by
the number of ﬂavoenzymes that are involved in the biosynthesis
of other cofactors such as coenzyme A, coenzyme Q (ubiquinone),
heme and pyridoxal 50-phosphate. Equally, ﬂavoenzymes partici-
pate in the interconversion of various folate metabolites and henceplay an important role in one-carbon (C1-unit) metabolism. More-
over, ﬂavoenzymes catalyze essential reactions in biosynthetic
pathways leading to cell signaling molecules such as the steroid
and thyroid hormones. These topics are discussed in more depths
in the next sections.
Flavoenzymes in folate and cobalamin metabolism
Tetrahydrofolate (THF) is a 6-methylpterin derivative that is
widely used to shuttle C1-units in metabolic reactions. THF loaded
with a C1-unit occurs in various oxidation states such as N-5,10-
methylene-THF and N-5-methyl-THF. Two FAD-dependent en-
zymes, dimethylglycine dehydrogenase (EC 1.5.99.2, DMGDH)
and sarcosine dehydrogenase (EC 1.5.99.1, SARDH), generate N-
5,10-methylene-THF from THF which is then converted to N-5-
methyl-THF by N-5,10-methylene-THF reductase (EC 1.5.1.20,
MTHFR) at the expense of NADPH (Fig. 1). N-5-methyl-THF in turn
is utilized by methionine synthase (EC 2.1.1.13, MS) yielding THF
and methionine by transferring the methyl group to homocysteine.
The cobalamine cofactor of MS is susceptible to oxidation and
hence methionine synthase reductase (EC 1.16.1.8, MSR) is re-
quired to regenerate methylcob(I)alamin from cob(II)alamin.
Hence, these four ﬂavin-dependent enzymes play a role in the inter
conversion of THF, N-5,10-methylene-THF and N-5-methyl-THF
and are thus important to balance the pools of folate metabolites
(Fig. 1).
DMGDH and SARDH also catalyze two consecutive reactions in
choline catabolism (Fig. 1). DMGDH oxidizes dimethlyglycine to
sarcosine, which is further oxidized to glycine. Both enzymes use
THF to capture the C-1 fragment released by the oxidative demeth-
ylation of substrates yielding N-5,10-methylene-THF [8]. Since
these reactions occur in the mitochondrial matrix, electrons ex-
tracted from the substrate are delivered to the mitochondrial elec-
tron transport chain via electron transferring ﬂavoprotein (ETF)
and electron transferring ﬂavoprotein ubiquinone oxidoreductase
(EC 1.5.5.1). DMGDH and SARDH were reported to contain a cova-
lently linked 8a-(N3-His)-FAD cofactor [9,10] and hence belong to
the small group of ﬂavoproteins that bind the cofactor covalently
(see Table 1). Unfortunately, the structure of these proteins is not
known and therefore neither the mode of FAD binding nor the
interaction with THF can be ﬁrmly established. Interestingly, a re-
cently discovered lysine-speciﬁc histone demethylase (EC 1.5.99.-,
KDM1A) related to ﬂavin-dependent amine oxidases apparently
does not utilize THF to capture the formyl group and hence the
demethylation results in the generation of formaldehyde [11].
Since the lysine demethylation occurs in the nucleus and not in
mitochondria, the enzyme donates the electrons to oxygen gener-
ating hydrogen peroxide as a by-product of the demethylation
reaction. The fate of these two potentially harmful compounds in
the nucleus is currently not known. A recent study showed that
inhibitors of KDM1A selectively target cancer cells with pluripo-
tent stem cell properties [12]. In light of these recent ﬁndings it
can be concluded that aberrations in KDM1A regulation might lead
to development of cancer.
Deﬁciency of DMGDH is apparently very rare and only a single
case was reported so far (OMIM 605850, [13,14]). Binzak et al.
identiﬁed a homozygous point mutation in a patient (326 A–G)
resulting in a histidine to arginine exchange (H109R) in the en-
coded DMGDH [13]. It is noteworthy that the covalent linkage of
the FAD cofactor is to H91 and hence the inactivity of the altered
enzyme is probably not due to the inability to form the covalent
linkage with the FAD cofactor. Detailed studies with the recombi-
nant DMGDH H109R variant showed effects on both the speciﬁc
activity (27 times lower) and Km (65 times higher) [15]. Interest-
ingly, ﬁsh odor was reported as a salient symptom of DMGDH deﬁ-
ciency which is typically ascribed to impaired N-oxygenation of
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isoform 3 (EC 1.14.13.8, FMO3) [16].
Sarcosinemia caused by a deﬁciency of SARDH [17] is also a rare
metabolic disorder characterized by elevated levels of sarcosine in
plasma and urine. The mutational frequency in the human SARDH
gene apparently varies from 1:350000 to 1:3414. The clinical
symptoms reported to be associated with SARDH deﬁciency in-
clude mental retardation and loss of speech (OMIM 268900). Re-
cently, sarcosine was suggested to be a marker for the
invasiveness of prostate cancer cell lines [18]. In the same study,
it was also noted that reduced levels of SARDH activity led to the
induction of an invasive phenotype in benign prostate epithelial
cells. The connection of SARDH to cancer development and pro-
gression indicated by this study and the usefulness of sarcosine
as a tumor marker is currently the subject of an intense scientiﬁc
debate [19–21].
MTHFR connects the pool of N-5,10-methylene-THF, mainly de-
rived from the glycine cleavage system (EC 2.1.2.10) and serine
hydroxymethyltransferase (EC 2.1.2.1), with that of N-5-methyl-
THF, which is used by MS to generate methionine from homocys-
teine (Fig. 1). This reaction not only provides an important building
block for protein biosynthesis but also a substrate for the synthesis
of S-adenosyl-methionine (SAM), an ubiquitous and powerful re-
agent in many biological methylation reactions. The MS reaction
also regenerates THF, which then re-enters the reactions men-
tioned above capturing C1-units from glycine, serine, dimethylgly-
cine and sarcosine. More than thirty deleterious mutations of the
MTHFR gene are known as well as several common variants, like
the 677C>T point mutation. MTHFR deﬁciency is connected to sev-
eral serious diseases, such as neural tube defects, coronary heart
disease and schizophrenia (OMIM 607093). Depending on the
severity of the mutation hyperhomocysteinemia with homocysti-
nuria or mild hyperhomocysteinemia is observed. The 677C>T
polymorphism is of particular interest as it is recognized as theOCH3
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Fig. 1. Flavin-catalyzed reactions connected to folate metabolism: dimethlyglycine dehy
5,10-methylene-tetrahydrofolate reductase (EC 1.5.1.20, MTHFR) and methionine syntha
synthase reductase (2qtl) as well as the N-5,10-methylene-tetrahydrofolate reductase frmost frequent genetic cause of homocysteinemia [22,23]. This
common C to T mutation gives rise to a conservative amino acid
replacement in position 222 of MTHFR (A222V). Surprisingly, the
A222V variant possesses reduced thermostability and weaker
afﬁnity to the FAD cofactor. In the same study it was also reported
that folate (and adenosylmethionine) increases the afﬁnity of FAD,
which in turn increases the thermostability of the A222V variant
[24]. This positive interplay suggests that the status of folate and
riboﬂavin may be critical in cases where cofactor afﬁnity is com-
promised by the amino acid exchange (see discussion above).
Mechanistically, MS uses N-5-methyl-THF to methylate its
cob(I)alamin cofactor which in turn transfers the methyl group to
the thiol group of homocysteine (Fig. 1). The cob(I)alamin state is
highly sensitive to oxidation rendering the enzyme inactive [25].
In order to restore the reduced active form of the cofactor,
cob(II)alamin is reductively methylated by MSR using NADPH as
electron source and SAM as methyl group donor [26,27]. Since
MSR is required to maintain MS activity, it is not surprising that
allelic variants resulting in MSR deﬁciency present similar symp-
toms, such as homocystinuria, as seen in MS and MTHFR deﬁ-
ciency. Accordingly, megaloblastic anemia, an increased risk for
neural tube defect and Down syndrome are among the disorders
caused by inherited MSR deﬁciency (OMIM 602568). A common
polymorphism found in the MSR gene (allele frequency 0.51) re-
sults in a single amino acid replacement, I23M, and increases the
risk for neural tube defects [25,28].
Recently, Matthews and coworkers suggested that MSR also
plays a role as a chaperone for MS and also acts as an aquacobala-
min reductase [29]. They reported that MSR stabilizes the apo-
form of MS and promotes the association with methylcobalamin.
In addition, MSR catalyzes the NADPH-dependent reduction of
aquacobalamin to cob(II)alamin and thereby accelerates the for-
mation of holo-MS. Hence, MSR exhibits multiple beneﬁcial effects
on MS. In this context, it is interesting to note that MSR was also3apt
+ H+ +H  NADP homocysteine methionine
-5-m -N ethyl THF THF
MS
C 2 1 1 13
MTHFR
EC 1.5.1.20 E  . . .
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drogenase (EC 1.5.99.1, DMGDH), sarcosine dehydrogenase (EC 1.5.99.2, SARDH), N-
se reductase (EC 1.16.1.8, MSR). Structures depicted are from the human methionine
om Thermus thermophilus HB8 (3apt).
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[25,30]. Recent evidence, however, suggests that reduction of
Co2+ to Co+ occurs by free dihydroﬂavins when cob(II)alamin is
bound to human adenosyltransferase [31]. It is currently unknown
whether this process is driven solely by free dihydroﬂavins or in-
volves a specialized ﬂavoprotein reductase in vivo.
Heme biosynthesis
The biosynthesis of heme from succinyl-CoA and glycine is ini-
tiated in the mitochondria and then proceeds in the cytosol to gen-
erate coproporphyrinogen III. This intermediate is transported
back into mitochondria to complete the oxidation of the macrocy-
cle by the FAD-dependent protoporphyrinogen IX oxidase (EC
1.3.3.4, PPOX). This reaction involves the six-electron oxidation
of the methylene groups linking the pyrrole rings to methenyl
groups thereby generating an extensively conjugated p-electron
system (Fig. 2). As the isoalloxazine ring system can only handle
two electrons at a time, the cofactor needs to run three times
through the catalytic cycle of ﬂavin reduction and reoxidation to
complete the oxidation of protoporphyrinogen IX to protoporphy-
rin IX. This catalytic cycling was suggested to proceed by substrate
oxidation and release of the dihydro- and tetrahydro-intermedi-
ates rather than continuous processing of a constantly bound sub-
strate [32]. PPOX is located in the inner mitochondrial membrane
and anchored by acylation to the leaﬂet oriented towards the inter-
membrane space [33,34]. Diminished PPOX activity results in var-
iegate porphyria (VP), which belongs to a group of metabolic
disturbances caused by genetic defects affecting heme biosynthesis
(collectively called as porphyrias). Symptoms of autosomal domi-
nant VP include acute abdominal pain, neurological manifestations
and/or cutaneous photosensitivity [35]. Apparently, the disease is
characterized by severe, sometimes life-threatening, crisis trig-
gered by external factors (e.g. medication, toxins) [36]. Perhaps
the most controversial case of VP was postulated for King George
III (1738–1820) who suffered long episodes of mental and physical
illness culminating in the Regency crisis (1788–1789). According to
Macalpine & Hunter, King George III was afﬂicted by VP, a claim
supported by several pieces of evidence collected on ancestors
and descendants [37,38]. More recently, Cox et al. suggested that
high concentrations of arsenic in the medication administered to
the king may have triggered the episodes of VP [39].
The structure of the human enzyme was solved to 1.9 Å resolu-
tion (pdb code 3nks). Forty-seven variants of PPOX that were found
to cause VP in humans were heterologously expressed in Esche-
richia coli and the properties of the variants studied in vitro [40].
Based on the observed effects and the locus of the amino acid in
the structure of the enzyme the authors of that study classiﬁed3 O 3 H ONH HN NH N2 2 2
NH HN N HN
O O OO
3nksO O OO
Fig. 2. The penultimate reaction in heme biosynthesis involves the six-electron
oxidation of protoporphyrinogen-IX to protoporphyrin-IX by the FAD-dependent
protoporphyrinogen-IX oxidase (EC 1.3.3.4, PPOX) (human structure: 3nks).the variants according to their proposed effect on either FAD- or
substrate binding or structural alterations of the protein. Interest-
ingly, the Human Gene Mutation Database (www.hgmd.cf.ac.uk)
lists more than 130 mutations, which appear to be uniformly dis-
tributed over the entire length of the gene and concern invariant
amino acids as well as regions of variability.
Pyridoxal 50-phosphate biosynthesis
Pyridoxal 50-phosphate (PLP) serves as a cofactor in more than
140 distinct enzymatic activities and is arguably one of the most
utilized vitamin in nature. According to a recent analysis, the hu-
man genome contains 68 genes encoding proteins with a structural
fold typical for PLP-dependent enzymes [41]. Although functional
assignment of these enzymes was not possible in all cases (14 re-
mained unassigned) this result indicates that the supply of PLP is
critical for the maintenance of numerous metabolic activities espe-
cially in pathways involving biochemical transformations of amino
acids, e.g. PLP-dependent decarboxylations of amino acids to gen-
erate active amines and neurotransmitters. In humans, PLP is
mainly generated by enzymatic phosphorylation and oxidation of
pyridoxine and pyridoxamine. These two vitamers are available
either from nutritional sources or are produced in the course of
the degradation of PLP-containing enzymes. In the ﬁrst step, they
are phosphorylated by pyridoxal kinase and then oxidized by pyr-
idoxine 50-phosphate oxidase (EC 1.4.3.5, PNPO) to the active
cofactor PLP (Fig. 3). The three-dimensional structures of the en-
zyme from several bacteria as well as the recombinant human en-
zyme were determined by X-ray crystallography ([42], pdb code
1nrg). Interestingly, the structure of the E. coli enzyme features
two PLP binding sites, one in the active site near the ﬂavin’s isoal-
loxazine ring and a second closer to the surface of the dimeric pro-
tein ([43], pdb code 1g79). It is currently unclear whether the latter
binding site is identical to the tight binding site identiﬁed by func-
tional studies [43]. The human enzyme (261 amino acids) presum-
ably also features a second tight binding site for PLP, however its
exact location is currently not known [44]. Di Salvo et al. suggested
that this second tight binding site might serve as transient storage
for PLP, which is channeled to the apo-forms of PLP-dependent en-
zymes [44]. In support of this hypothesis, these authors reported
that PNPO from E. coli interacts with several apo-forms of PLP-
dependent enzymes with dissociation constants in the micromolar
range (0.3–56 lM; [44]). Although this appears to be an attractive
process for the delivery of PLP to its target enzymes, it is unlikely
that this is applicable to all human PLP-dependent enzymes be-
cause it would require a common docking site between the single
PNPO and the 68 predicted enzymes. On the other hand, PNPO’s
cytosolic localization would enable the enzyme to deliver PLP di-
rectly to the apo-form of PLP-depenent enzymes in statu nascendi.
Several allelic variants of the PNPO gene were described (OMIM
603287). The reported mutations either lead to premature termi-
nation of protein biosynthesis (at position 174 [45]), extension of
the protein by 28 amino acids (X262N) or splicing errors due to a
mutation in intron 3 [46]. In addition, Mills et al., reported a point
mutation in the PNPO gene resulting in the substitution of arginine
in position 229 with tryptophan [46]. This R229W variant was
recombinantly expressed and characterized by Musayev et al.
[47]. They found that this variant is substantially compromised
in its catalytic efﬁciency (ca. 850-fold) due to weaker binding of
the substrate and decreased catalytic activity. Moreover, FMN pos-
sessed a 50-fold reduced afﬁnity to the variant (see discussion
above). These effects could be rationalized based on the involve-
ment of the arginine residue in organizing important interactions
in the active site of the enzyme. All of the reported mutations
caused severe deﬁciency of PNPO activity resulting in neonatal epi-
leptic encephalopathy. This disorder has a very poor prognosis
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Fig. 3. Oxidation of pyridoxamine and pyridoxine 50-phosphate to pyridoxal 50-phosphate by the FMN-dependent pyridoxamine/pyridoxine 50-phosphate oxidase (EC 1.4.3.5,
PNPO), the last step of the PLP-biosynthesis. The structure shown is that of the human enzyme (1nrg).
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retardation.
PNPO expression in humans is prevalent in liver and kidney
with most other tissues (brain, heart, muscle) having clearly re-
duced levels of mRNA [48]. Interestingly, abnormally low levels
of PNPO activity were reported for some neoplastic cell lines, e.g.
liver and neurally-derived tumors [49]. Whether and how these
low PNPO activities are connected to tumorigenesis remains to
be investigated.OP
O
O
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Fig. 4. Decarboxylation of N-[(R)-40-phosphopantothenoyl]-L-cysteine to panto-
theine 40-phosphate by the FMN-dependent 40-phosphopantothenoylcysteine
decarboxylase (EC 4.1.1.36, PPCDC). The structure shown is that of the human
enzyme (1qzu).
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Fig. 5. Hydroxylation of the ubiquinone precursors in 5-position of the aromatic
system by COQ6 (EC 1.14.99.-). In yeast, the electrons required for reduction of
dioxygen are supplied by an NADPH-dependent ferredoxin reductase-ferredoxin
system.Coenzyme A biosynthesis
Coenzyme A (CoA) biosynthesis from pantothenic acid (vitamin
B5) is a ﬁve-step enzymatic process. The third reaction in this
universal reaction sequence is the decarboxylation of phosphopan-
tothenoylcysteine to 40-phosphopantetheine by phosphopantothe-
noylcysteine decarboxylase (EC 4.1.1.36; PPCD) as shown in Fig. 4
[50]. The structure of the human enzyme shows a non-covalently
bound FMN per protomer of the trimeric protein [51]. In eukary-
otes PPCD occurs as a monofunctional enzyme whereas in most
bacteria – with the exception of streptococci and enterococci –
PPCD is fused with phosphopantothenoylcysteine synthase (PPCS)
the second enzyme of CoA biosynthesis [50]. In contrast to the
reactions described above, the decarboxylation does not involve a
net redox change. PPCD is one of the few examples where the
ﬂavin is not used for a reduction–oxidation reaction in a human
ﬂavoprotein (Table 1, entry #67). However, the ﬂavin apparently
plays a role as a transient electron acceptor during the reaction
involving the transfer of charge from the substrate thiolate group
to the isoalloxazine ring [52]. Currently, the OMIM database does
not list any diseases related to a deﬁciency of PPCD. This may be
partly due to the fact that approximately 4% of all enzymes utilize
substrates linked to coenzyme A (e.g. acyl-CoAs) [53] and hence a
deﬁciency in coenzyme A seriously compromises the viability of
cells. This notion is supported by the fact that only the initial
enzyme of coenzyme A biosynthesis, pantothenate kinase (EC
2.7.1.33, PANK), is linked to inherited diseases (OMIM 606157)
but none of the other enzymes required. Interestingly, four iso-
forms of PANK were discovered in the human genome and there-
fore it appears likely that a deﬁciency of one isoform may be
compensated at least partially by the others [54].Coenzyme Q biosynthesis
Coenzyme Q or ubiquinone is an essential electron carrier in the
mitochondrial electron transport chain shuttling electrons from
complex I and II to complex III (see also section below). In contrast
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from aromatic precursors such as p-hydroxybenzoic acid. In
2011, Pierrel and coworkers identiﬁed a FAD-dependent monoox-
ygenase encoded by coq6, for the required hydroxylation in 5-posi-
tion of a ubiquinone precursor in the yeast Saccharomyces
cerevisiae (Fig. 5) [55]. A human homolog of coq6 was recently dis-
covered, which apparently catalyzes the hydroxylation in human
ubiquinone biosynthesis (Table 1, entry #59) [56]. Flavin-depen-
dent monooxygenases (hydroxylases) require a source of electrons
for reduction of the ﬂavin’s isoalloxazine ring in order to enable the
generation of hydroxylating 4a-hydroperoxy intermediates. Based
on the mode of ﬂavin reduction, internal and external monooxyge-
nases are distinguished which either use NAD(P)H or NADH di-
rectly for reduction or rely on the activity of an external
NAD(P)H/NADH:FAD reductase to supply the reduced ﬂavin cofac-
tor [57]. In the case of yeast Coq6p, reduction of FAD is accom-
plished by ferredoxin reductase (termed Arh1) and ferredoxin
(termed Yah1) at the expense of NADPH and thus has the character
of an external reduction mode. It is currently unknown whether
the human enzyme is reduced by the samemechanism. The human
ortholog of coq6 was discovered in search of the genetic cause of
nephrotic syndrome [56] and several reports of coenzyme Q deﬁ-
ciency are compiled in the OMIM (614647).Steroid biosynthesis
Steroid hormones play fundamental roles in developmental
programs and homeostatic processes. Cholesterol, a central precur-
sor for the biosynthesis of steroid hormones, bile acids and vitamin
D, is synthesized from acetyl-CoA via the mevalonate pathway in a
multistep pathway [58]. A crucial step in the biosynthesis is the
cyclisation of the linear 2,3-oxidosqualene to the ﬁrst tetracyclic
ring system, lanosterol. The preceding reaction, catalyzed by squa-
lene monooxygenase (EC 1.14.13.132, SQLE), enables this cyclisa-
tion by epoxidation of the 2,3-carbon–carbon double bond
(Fig. 6, top) [59]. The oxygen atom introduced by SQLE remains
in the molecule during processing to the steroid target structures
and is important for the physical (amphiphilic character) and
chemical properties (formation of esters). Although SQLE does
not appear to be linked to an inherited disease, it was suggested
earlier that the gene encoding SQLE is a candidate for Langer–
Giedion syndrome, which is associated with mental retardation
and microcephaly [60]. Interestingly, SQLE became a focus as aEC 1.14.13.
NADPH + H H2
HO
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Fig. 6. Reactions of the two FAD-dependent enzymes in cholesterol biosynthesis. The reac
1.14.13.132) and the reaction shown on the bottom the reduction of the side chain doudrug target for antimycotic compounds in the 1980s [61]. More
recently it is also discussed as a potentially useful target in
hypercholesterolemic therapy [62,63]. Currently, treatment of
hypercholesterolemia is dominated by statins, which inhibit 3-hy-
droxy-3-methylglutaryl CoA (HMG-CoA) reductase (EC 1.1.1.34), a
central and rate-limiting enzyme in the mevalonate pathway. A
major drawback of HMG-reductase inhibition results from the ad-
verse effects on the biosynthesis of non-steroidal isoprenoids (e.g.
ubiquinone) since the enzyme catalyzes an ‘‘early’’ step in the
pathway. To alleviate this problem steps occurring after the com-
mitting reaction of steroid biosynthesis, i.e. the synthesis of squa-
lene from farnesylpyrophosphate catalyzed by squalene synthase
(EC 2.5.1.21) might be potentially useful targets for the design of
new cholesterol lowering compounds. Because SQLE is the next en-
zyme of this metabolic branch point it is a suitable point of inter-
vention to reduce the biosynthesis of cholesterol [62,63].
The ultimate reaction in cholesterol biosynthesis, the reduction
of desmosterol, is catalyzed by 3b-hydroxysterolD24-reductase (EC
1.3.1.72, DHCR24). In contrast to SQLE, DHCR24 does not activate
dioxygen for insertion into the substrate, but simply reduces the
side-chain double bond at the expense of NADPH (Fig. 6, bottom).
The gene encoding DHCR24 is a human homolog (also termed sel-
adin-1) of the DIMINUTO/DWARF1 gene found in plants and Caeno-
rhabditis elegans [64]. Several mutations in the human gene are
known which result in reduced enzyme activity leading to desmos-
terolosis (OMIM 606418). Some of the mutations discovered are in
or near the FAD binding site and hence may affect FAD binding. In
other cases, however, the mutation is in less conserved areas and
their effect on protein structure, folding or stability is unclear.
Symptoms of the disease present at or shortly after birth and show
a diverse range of developmental anomalies, such as failure to
thrive, micro- or macrocephaly, psychomotor retardation, spastic-
ity and seizures. The observed developmental and neurological de-
fects correspond to the high expression of the gene in neuronal
cells [64]. More recently it was also shown that DHCR24 is impor-
tant for long bone growth in mice indicating that the enzyme’s
activity is also critical for the development of other tissues [65].Thyroxine biosynthesis and iodine salvage
The thyroid gland produces two iodinated tyrosine-derived hor-
mones, triidothyronine (T3) and thyroxine (T4), which stimulate
metabolism in most tissues. The initial biosynthetic reaction132
O
O
HO
DP
2,3-oxidosqualene
cholesterol
tion shown on top involves the insertion of an oxygen atom (blue circle) by SQLE (EC
ble bond (green circle) by DHCR24 (EC 1.3.1.72).
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Fig. 7. Role of DUOX1 and 2 in the biosynthesis of thyroxine. The iodination of tyrosine residues and the coupling of two iodinated tyrosines require hydrogen peroxide,
which is provided by the oxidation of reduced FAD with molecular dioxygen.
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globulin. In the next step, two neighboring iodotyrosine residues
are oxidatively coupled and the active hormones, T3 and T4, are re-
leased by proteolytic cleavage of the precursor protein. The iodin-
ation and coupling reaction both require hydrogen peroxide, which
is provided by two FAD-dependent thyroid oxidases (termed
DUOX1 and 2) [66,67]. During turnover, FAD is reduced at the ex-
pense of NADPH and then reoxidized by dioxygen yielding hydro-
gen peroxide (Fig. 7). Several allelic variants were reported for
DUOX2 leading to thyroid dyshormonogenesis 6 (OMIM 606759).
How the resulting single amino acid exchange in the observed vari-
ants affect enzyme function is currently not known.
During the production of T3 and T4 substantial amounts of
mono- and diiodotyrosine are released [68]. Because iodine is a
precious trace element, it is recycled in a single reductive step cat-
alyzed by an FMN-dependent dehalogenase (IYD, Fig. 8 [69]). The
released iodine can then be reused by thyroperoxidase for incorpo-
ration into thyroglobulin (see above). Several allelic variants were
reported for IYD, which severely compromise the dehalogenase
activity of the enzyme leading to hypothyroidism (dyshormono-
genesis 4, OMIM 612025) [70,71].Flavoproteins providing assistance to other ﬂavoproteins: Assembly of
complex I
The human respiratory electron transport chain relies on com-
plex I for electron transfer from NADH to ubiquinone coupled with
proton translocation across the inner mitochondrial membrane. In
the initial reaction NADH reduces the FMN cofactor in the NDUFV1
subunit (EC 1.6.5.3) of complex I, which in turn passes the elec-
trons to iron-sulfur clusters. The formation of complex I, whichH3N CH COO
CH2
OH
IYD
I
iodotyrosine
H3N CH COO
CH2
OH
FMNH2 FMN
+ I
Fig. 8. Dehalogenation of iodotyrosine catalyzed by IYD. The mono- and diiodo-
tyrosine residues released from thyroglobulin are substrates of the enzyme.
Reductively released iodine is then reused by thryoperoxidase for incorporation
into tyrosine residues of thyroglobulin.consists of at least 36 nuclear- and seven mitochondrial-encoded
subunits (OMIM 252010), requires several assembly factors, such
as NDUFAF1 and NUBPL [72,73]. In addition, two FAD-dependent
proteins recently emerged as critical factors for complex I assem-
bly, ACAD9 and FOXRED1 (Table 1, entries #24 and #73, respec-
tively). The exact role of the FAD-dependent OXidoREDuctase
(FOXRED1) in assembly of complex I is not fully understood at
the moment but it was clearly shown that it is essential for com-
plex I activity in the inner mitochondrial membrane [72,74]. A
BLASTp search identiﬁed two human FAD-dependent ﬂavopro-
teins, SARDH and DMGDH, as related (22% and 21% identity,
respectively) enzymes to FOXRED1. FOXRED1 comprises 486 ami-
no acids and thus is much shorter than SARDH and DMGDH with
918 and 866 amino acids, respectively. The similarity of FOXRED1
to SARDH and DMGDH is found in the N-terminal part of the two
dehydrogenases where FAD is covalently bound to a histidine. This
amino acid residue is not conserved in FOXRED1 indicating that the
FAD cofactor may not be covalently bound.
The discovery of FOXRED1 was closely associated with the
search to identify the mechanism of complex I deﬁciency, leading
for example to mitochondrial encephalopathy. Fassone et al. dem-
onstrated that a point mutation in the FOXRED1 gene led to an
amino acid exchange (R352W) in the putative FAD binding site
[74]. According to their molecular model of the protein this amino
acid exchange could prevent FAD binding and hence compromises
the assumed chaperone activity of the protein.
ACAD9 (EC 1.3.99.-) was ﬁrst described as an acyl-CoA dehydro-
genase speciﬁc for long-chain unsaturated fatty acids [75,76]. Re-
cent evidence however questions the involvement of ACAD9 in
the degradation of long-chain fatty acids in the mitochondrial ma-
trix and suggests a role in biogenesis of complex I instead [77].
Although recombinant ACAD9 possesses dehydrogenase activity
in vitro, mutations in ACAD9 result in complex I deﬁciency rather
than a disturbance of long-chain fatty acid metabolism [77].Concluding remarks
Our analysis of the human ﬂavoproteome has led to the identi-
ﬁcation of several areas where further research is required. Be-
cause riboﬂavin must be supplied by the diet uptake in the
human intestine is an important process to make the vitamin avail-
able for the synthesis of FMN and FAD. Three poorly characterized
transporters seem to be responsible for riboﬂavin uptake in the hu-
man intestine. The relative contribution and role of these
W.-D. Lienhart et al. / Archives of Biochemistry and Biophysics 535 (2013) 150–162 161transporters is currently unclear and warrants further investiga-
tions. A better understanding of the uptake processes may also
have therapeutic beneﬁts as some inherited diseases feature re-
duced ﬂavin afﬁnity to the affected ﬂavoproteins and thus are
potentially treatable by riboﬂavin supplementation. Equally, little
is known about ﬂavin homeostasis and the processes leading to
degradation and excretion of ﬂavins.
Although many human ﬂavoprotein structures were solved
experimentally by X-ray crystallography or modeled using homol-
ogous structures several ﬂavoproteins still elude structural charac-
terisation. Many of these are associated with cellular membranes
and are therefore more difﬁcult to obtain by recombinant expres-
sion in heterologous hosts. Moreover, membrane integral or asso-
ciated proteins are challenging for structure elucidation by X-ray
crystallography due to their lipophilic character. In view of the
important roles of membrane-associated ﬂavoproteins in humans,
the potential as drug targets (e.g. SQLE) and the involvement in dis-
eases (e.g. DUOX1/2, IYD) determination of the ‘‘missing’’ struc-
tures are certainly rewarding goals.
We found that many genes encoding ﬂavoproteins occur as alle-
lic variants with the potential to cause severe human diseases
(Table 2). The number of allelic variants covers a wide range from
only a few to more than one hundred. With the exception of a few
systematic studies our knowledge of the effect of the mutation on
stability, structure and activity of the ﬂavoprotein is incomplete.
This lack of insight should be improved by detailed analyses of
mutational effects on ﬂavoprotein properties. In light of many indi-
cations that ﬂavoprotein variants suffer from a reduced afﬁnity to
their cognate ﬂavin cofactor this seems to be of particular impor-
tance because riboﬂavin supplementation may help to remedy
symptoms in affected individuals.
Methods
The names and gene abbreviations of human ﬂavoproteins,
compiled for a previously published review article [2], were used
to search for inherited diseases in the Online Mendalian Inheri-
tance in Man data base (OMIM; http://www.ncbi.nlm.nih.gov/
omim). This search constituted the basis for Table 2 where the
most relevant entry in OMIM is provided as a six-digit number
(right column). The reader is referred to these entries for a com-
plete list of references pertaining to the diseases mentioned in this
article.
Acknowledgments
We thank the Austrian Research Fund (FWF) for ﬁnancial sup-
port through project P22361 and the PhD program ‘‘Molecular
Enzymology’’ (W901).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.abb.2013.02.015.
References
[1] J.L. Chastain, D.B. McCormick, Am. J. Clin. Nutr. 46 (1987) 830–834.
[2] P. Macheroux, B. Kappes, S.E. Ealick, FEBS J. 278 (2011) 2625–2634.
[3] B.N. Ames, I. Elson-Schwab, E.A. Silver, Am. J. Clin. Nutr. 75 (2002) 616–658.
[4] A.M. Bosch, N.G. Abeling, L. Ijlst, H. Knoester, W.L. van der Pol, A.E. Stroomer,
R.J. Wanders, G. Visser, F.A. Wijburg, M. Duran, et al., J. Inherit. Metab. Dis. 34
(2011) 159–164.
[5] P. Green, M. Wiseman, Y.J. Crow, H. Houlden, S. Riphagen, J.P. Lin, F.L.
Raymond, A.M. Childs, E. Sheridan, S. Edwards, et al., Am. J. Hum. Gen. 86
(2010) 485–489.
[6] G. Anand, N. Hasan, S. Jayapal, Z. Huma, T. Ali, J. Hull, E. Blair, T. McShane, S.
Jayawant, Dev. Med. Child Neurol. 54 (2012) 187–189.[7] A. Koy, F. Pillekamp, T. Hoehn, H. Waterham, D. Klee, E. Mayatepek, B.
Assmann, Pediatr. Neurol. 46 (2012) 407–409.
[8] A.J. Wittwer, C. Wagner, J. Biol. Chem. 256 (1981) 4102–4108.
[9] R.J. Cook, K.S. Misono, C. Wagner, J. Biol. Chem. 259 (1984) 12475–12480.
[10] R.J. Cook, K.S. Misono, C. Wagner, J. Biol. Chem. 260 (1985) 12998–13002.
[11] F. Forneris, E. Battaglioli, A. Mattevi, C. Binda, FEBS J. 276 (2009) 4304–4312.
[12] J. Wang, F. Lu, Q. Ren, H. Sun, Z. Xu, R. Lan, Y. Liu, D. Ward, J. Quan, T. Ye, et al.,
Cancer Res. 71 (2011) 7238–7249.
[13] B.A. Binzak, R.A. Wevers, S.H. Moolenaar, Y.M. Lee, W.L. Hwu, J. Poggi-Bach,
U.F. Engelke, H.M. Hoard, J.G. Vockley, J. Vockley, Am. J. Hum. Gen. 68 (2001)
839–847.
[14] S.H. Moolenaar, J. Poggi-Bach, U.F. Engelke, J.M. Corstiaensen, A. Heerschap,
J.G. de Jong, B.A. Binzak, J. Vockley, R.A. Wevers, Clin. Chem. 45 (1999) 459–
464.
[15] R.P. McAndrew, J. Vockley, J.J. Kim, J. Inherit. Metab. Dis. 31 (2008) 761–768.
[16] E.P. Treacy, B.R. Akerman, L.M. Chow, R. Youil, C. Bibeau, J. Lin, A.G. Bruce, M.
Knight, D.M. Danks, J.R. Cashman, et al., Hum. Mol. Gen. 7 (1998) 839–845.
[17] M. Eschenbrenner, M.S. Jorns, Genomics 59 (1999) 300–308.
[18] A. Sreekumar, L.M. Poisson, T.M. Rajendiran, A.P. Khan, Q. Cao, J. Yu, B. Laxman,
R. Mehra, R.J. Lonigro, Y. Li, et al., Nature 457 (2009) 910–914.
[19] L. Bohm, A.M. Seraﬁn, P. Fernandez, G. Van der Watt, P.J. Bouic, J. Harvey, S. Afr.
Med. J. 102 (2012) 677–679.
[20] H.J. Issaq, T.D. Veenstra, J. Sep. Sci. 34 (2011) 3619–3621.
[21] G. Lucarelli, M. Fanelli, A.M. Larocca, C.A. Germinario, M. Rutigliano, A. Vavallo,
F.P. Selvaggi, C. Bettocchi, M. Battaglia, P. Ditonno, Prostate 72 (2012) 1611–
1621.
[22] P. Frosst, H.J. Blom, R. Milos, P. Goyette, C.A. Sheppard, R.G. Matthews, G.J.
Boers, M. den Heijer, L.A. Kluijtmans, L.P. van den Heuvel, et al., Nat. Gen. 10
(1995) 111–113.
[23] P.M. Ueland, S. Hustad, J. Schneede, H. Refsum, S.E. Vollset, Trends Pharmacol.
Sci. 22 (2001) 195–201.
[24] K. Yamada, Z. Chen, R. Rozen, R.G. Matthews, Proc. Natl. Acad. Sci. USA 98
(2001) 14853–14858.
[25] D. Leclerc, A. Wilson, R. Dumas, C. Gafuik, D. Song, D. Watkins, H.H. Heng, J.M.
Rommens, S.W. Scherer, D.S. Rosenblatt, et al., Proc. Natl. Acad. Sci. USA 95
(1998) 3059–3064.
[26] M.L. Ludwig, R.G. Matthews, Annu. Rev. Biochem. 66 (1997) 269–313.
[27] H. Olteanu, R. Banerjee, J. Biol. Chem. 276 (2001) 35558–35563.
[28] A. Wilson, R. Platt, Q. Wu, D. Leclerc, B. Christensen, H. Yang, R.A. Gravel, R.
Rozen, Mol. Gen. Metab. 67 (1999) 317–323.
[29] K. Yamada, R.A. Gravel, T. Toraya, R.G. Matthews, Proc. Natl. Acad. Sci. USA 103
(2006) 9476–9481.
[30] N.A. Leal, H. Olteanu, R. Banerjee, T.A. Bobik, J. Biol. Chem. 279 (2004) 47536–
47542.
[31] P.E. Mera, J.C. Escalante-Semerena, J. Biol. Chem. 285 (2010) 2911–2917.
[32] H.A. Dailey, Biochem. Soc. Trans. 30 (2002) 590–595.
[33] S. Arnould, M. Takahashi, J.-M. Camadro, Proc. Natl. Acad. Sci. USA 96 (1999)
14825–14830.
[34] J.C. Deybach, V. da Silva, B. Grandchamp, Y. Nordmann, Eur. J. Biochem. 194
(1985) 431–435.
[35] S. Sassa, Br. J. Haematol. 135 (2006) 281–292.
[36] H. Puy, L. Gouya, J.C. Deybach, Lancet 375 (2010) 924–937.
[37] I. Macalpine, R. Hunter, Br. Med. J. 1 (1966) 65–71.
[38] J.C.G. Röhl, M.J. Warren, D.M. Hunt, Purple Secret, Genes, ‘‘Madness’’ and the
Royal Houses of Europe, Bantam Press, London, 1998.
[39] T.M. Cox, N. Jack, S. Lofthouse, J. Watling, Lancet 366 (2005) 332–335.
[40] X. Qin, Y. Tan, L. Wang, Z. Wang, B. Wang, X. Wen, G. Yang, Z. Xi, Y. Shen, FASEB
J. 25 (2011) 653–664.
[41] R. Percudani, A. Peracchi, EMBO Rep. 4 (2003) 850–854.
[42] F.N. Musayev, M.L. Di Salvo, T.-P. Ko, V. Schirch, M.K. Safo, Protein Sci. 12
(2003) 1455–1463.
[43] M.K. Safo, F.N. Musayev, M.L. Di Salvo, V. Schirch, J. Mol. Biol. 310 (2001) 817–
826.
[44] M.L. Di Salvo, R. Contestabile, M.K. Safo, Biochim. Biophys. Acta 1814 (2011)
1597–1608.
[45] A. Ruiz, J. Garcia-Villoria, A. Ormazabal, J. Zschocke, M. Fiol, A. Navarro-Sastre,
R. Artuch, M.A. Vilaseca, A. Ribes, Mol. Gen. Metab. 93 (2008) 216–218.
[46] P.B. Mills, R.A. Surtees, M.P. Champion, C.E. Beesley, N. Dalton, P.J. Scambler,
S.J. Heales, A. Briddon, I. Scheimberg, G.F. Hoffmann, et al., Hum. Mol. Gen. 14
(2005) 1077–1086.
[47] F.N. Musayev, M.L. Di Salvo, M.A. Saavedra, R. Contestabile, M.S. Ghatge, A.
Haynes, V. Schirch, M.K. Safo, J. Biol. Chem. 284 (2009) 30949–30956.
[48] J.H. Kang, M.L. Hong, D.W. Kim, J. Park, T.C. Kang, M.H. Won, N.I. Baek, B.J.
Moon, S.Y. Choi, O.S. Kwon, Eur. J. Biochem. 271 (2004) 2452–2461.
[49] E.O. Ngo, G.R. LePage, J.W. Thanassi, N. Meisler, L.M. Nutter, Biochemistry 37
(1998) 7741–7748.
[50] M. Daugherty, B. Polanuyer, M. Farrell, M. Scholle, A. Lykidis, V. de Crecy-
Lagard, A. Osterman, J. Biol. Chem. 277 (2002) 21431–21439.
[51] N. Manoj, S.E. Ealick, Acta Crystallogr. 59 (2003) 1762–1766.
[52] S. Steinbacher, P. Hernandez-Acosta, B. Bieseler, M. Blaesse, R. Huber, F.A.
Culianez-Macia, T. Kupke, J. Mol. Biol. 327 (2003) 193–202.
[53] T.P. Begley, C. Kinsland, E. Strauss, Vitam. Horm. 61 (2001) 157–171.
[54] B. Zhou, S.K. Westaway, B. Levinson, M.A. Johnson, J. Gitschier, S.J. Hayﬂick,
Nat. Gen. 28 (2001) 345–349.
[55] M. Ozeir, U. Muhlenhoff, H. Webert, R. Lill, M. Fontecave, F. Pierrel, Chem. Biol.
18 (2011) 1134–1142.
162 W.-D. Lienhart et al. / Archives of Biochemistry and Biophysics 535 (2013) 150–162[56] S.F. Heeringa, G. Chernin, M. Chaki, W. Zhou, A.J. Sloan, Z. Ji, L.X. Xie, L. Salviati,
T.W. Hurd, V. Vega-Warner, et al., J. Clin. Invest. 121 (2011) 2013–2024.
[57] W.J. van Berkel, N.M. Kamerbeek, M.W. Fraaije, J. Biotech. 124 (2006) 670–689.
[58] G. Gibbons, K. Mitropoulos, N. Myant, Biochemistry of Cholesterol, Elsevier
Biomedical, Amsterdam, 1982.
[59] S. Yamamoto, K. Bloch, J. Biol. Chem. 245 (1970) 1670–1674.
[60] M. Nagai, J. Sakakibara, K. Wakui, Y. Fukushima, S. Igarashi, S. Tsuji, M.
Arakawa, T. Ono, Genomics 44 (1997) 141–143.
[61] N.S. Ryder, M.C. Dupont, Biochem. J. 230 (1985) 765–770.
[62] A. Belter, M. Skupinska, M. Giel-Pietraszuk, T. Grabarkiewicz, L. Rychlewski, J.
Barciszewski, Biol. Chem. 392 (2011) 1053–1075.
[63] A. Chugh, A. Ray, J.B. Gupta, Prog. Lipid Res. 42 (2003) 37–50.
[64] I. Greeve, I. Hermans-Borgmeyer, C. Brellinger, D. Kasper, T. Gomez-Isla, C.
Behl, B. Levkau, R.M. Nitsch, J. Neurosci. 20 (2000) 7345–7352.
[65] R. Mirza, S. Qiao, K. Tateyama, T. Miyamoto, L. Xiuli, H. Seo, J. Bone Miner.
Metab. 30 (2012) 144–153.
[66] X. De Deken, D. Wang, M.C. Many, S. Costagliola, F. Libert, G. Vassart, J.E.
Dumont, F. Miot, J. Biol. Chem. 275 (2000) 23227–23233.
[67] C. Dupuy, R. Ohayon, A. Valent, M.S. Noel-Hudson, D. Deme, A. Virion, J. Biol.
Chem. 274 (1999) 37265–37269.
[68] J. Nunez, J. Pommier, Vitam. Horm. 39 (1982) 175–229.
[69] J.E. Friedman, J.A. Watson Jr., D.W. Lam, S.E. Rokita, J. Biol. Chem. 281 (2006)
2812–2819.
[70] G. Aﬁnk, W. Kulik, H. Overmars, J. de Randamie, T. Veenboer, A. van Cruchten,
M. Craen, C. Ris-Stalpers, J. Clin. Endocrinol. Metab. 93 (2008) 4894–4901.
[71] J.C. Moreno, W. Klootwijk, H. van Toor, G. Pinto, M. D’Alessandro, A. Leger, D.
Goudie, M. Polak, A. Gruters, T.J. Visser, N. Engl. J. Med. 358 (2008) 1811–1818.[72] S.E. Calvo, E.J. Tucker, A.G. Compton, D.M. Kirby, G. Crawford, N.P. Burtt, M.
Rivas, C. Guiducci, D.L. Bruno, O.A. Goldberger, et al., High-throughput, pooled
sequencing identiﬁes mutations in NUBPL and FOXRED1 in human complex I
deﬁciency, Nat. Gen. 42 (2010) 851–858.
[73] C.J. Dunning, M. McKenzie, C. Sugiana, M. Lazarou, J. Silke, A. Connelly, J.M.
Fletcher, D.M. Kirby, D.R. Thorburn, M.T. Ryan, EMBO J. 26 (2007) 3227–3237.
[74] E. Fassone, A.J. Duncan, J.W. Taanman, A.T. Pagnamenta, M.I. Sadowski, T.
Holand, W. Qasim, P. Rutland, S.E. Calvo, V.K. Mootha, et al., Hum. Mol. Gen. 19
(2010) 4837–4847.
[75] R. Ensenauer, M. He, J.M. Willard, E.S. Goetzman, T.J. Corydon, B.B. Vandahl,
A.W. Mohsen, G. Isaya, J. Vockley, J. Biol. Chem. 280 (2005) 32309–32316.
[76] J. Zhang, W. Zhang, D. Zou, G. Chen, T. Wan, M. Zhang, X. Cao, Biochem.
Biophys. Res. Commun. 297 (2002) 1033–1042.
[77] J. Nouws, L. Nijtmans, S.M. Houten, M. van den Brand, M. Huynen, H.
Venselaar, S. Hoefs, J. Gloerich, J. Kronick, T. Hutchin, et al., Cell. Metab. 12
(2010) 283–294.
[78] A. Mostowska, B. Biedziak, I. Dunin-Wilczynska, A. Komorowska, P.P.
Jagodzinski, Birth Defects Res. A Clin. Mol. Teratol. 91 (2011) 169–176.
[79] A. Mostowska, K.K. Hozyasz, B. Biedziak, J. Misiak, P.P. Jagodzinski, Eur. J. Oral.
Sci. 118 (2010) 325–332.
[80] A. Mostowska, K.K. Hozyasz, P. Wojcicki, M. Dziegelewska, P.P. Jagodzinski, J.
Med. Genet. 47 (2010) 809–815.
[81] A.R. Johnson, C.N. Craciunescu, Z. Guo, Y.W. Teng, R.J. Thresher, J.K. Blusztajn,
S.H. Zeisel, FASEB J. 24 (2010) 2752–2761.
[82] A.R. Johnson, S. Lao, T. Wang, J.A. Galanko, S.H. Zeisel, PLoS ONE 7 (2012)
e36047.
